Repository logo
  • Log In
    Log in via Symplectic to deposit your publication(s).
Repository logo
  • Communities & Collections
  • Research Outputs
  • Statistics
  • Log In
    Log in via Symplectic to deposit your publication(s).
  1. Home
  2. Faculty of Natural Sciences
  3. Chemistry
  4. Chemistry PhD theses
  5. N-myristoyltransferase inhibitor binding mode and phenotype in the malarial parasite.
 
  • Details
N-myristoyltransferase inhibitor binding mode and phenotype in the malarial parasite.
File(s)
Schlott-A-2019-PhD-Thesis-appendix.pdf (7.48 MB)
Thesis (Appendix)
Schlott-A-2019-PhD-Thesis.pdf (54.66 MB)
Thesis
Author(s)
Schlott, Anja Christine
Type
Thesis or dissertation
Abstract
Malaria continues to be a significant cause of death and morbidity worldwide and there is a need for new antimalarial drugs with novel targets. As a potential target for drug development against malaria, the focus of this thesis is on N-myristoyltransferase (NMT), an enzyme that acylates a wide range of substrate proteins. The NMT substrates in Plasmodium falciparum include proteins that are important in essential processes including parasite signalling pathways, protein transport, and host cell invasion. Myristoylation facilitates the interaction of proteins with membranes, which may be strengthened by further lipidation, and inhibition of NMT results in incorrect protein localization and consequent disruption of function. The diverse roles of NMT substrates mean that NMT inhibition has a pleiotropic and severe impact on parasite development, growth and multiplication. To study the mechanism of action underlying NMT inhibition it is important to consider the function of proteins upstream and downstream of NMT. The phenotype of loss of myristoylation on particular substrates in isolation, through genetic manipulation of the N-terminal glycine, gives insights in the essentiality of this mostly co-translational modification.

Because there is an increasing threat of resistance to all front-line drugs against malaria, it is important to study resistance development early in the drug development process. This could aid the selection of drug combinations and impede rapid evolution of parasite resistance. This thesis describes the first parasites resistance mechanism to a particular NMT inhibitor series and shows that resistance in an in vitro parasite growth assay is mediated by a single amino acid substitution in the NMT substrate binding pocket. The basis of resistance was validated and analysed with a structure-guided approach using crystallography, in combination with enzyme activity, stability and surface plasmon resonance-assays, allowing identification of another inhibitor series unaffected by this substitution.
Version
Open Access
Date Issued
2019-07
Date Awarded
2019-12
URI
http://hdl.handle.net/10044/1/85451
DOI
https://doi.org/10.25560/85451
Copyright Statement
Creative Commons Attribution NonCommercial Licence
License URL
https://creativecommons.org/licenses/by-nc/4.0/
Advisor
Holder, Anthony
Tate, Edward
Fuchter, Matthew
Blackman, Mike
Sponsor
Medicines for Malaria Venture
Seattle Structural Genomics Center for Infectious Disease (SSGCID)
Grant Number
Work in the Holder laboratory and Tate satellite laboratory was supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001097, FC010636), the UK Medical Research Council (FC001097, FC010636), and the Wellcome Trust (FC001097, FC010636).
Publisher Department
Chemistry
Publisher Institution
Imperial College London
Qualification Level
Doctoral
Qualification Name
Doctor of Philosophy (PhD)
About
Spiral Depositing with Spiral Publishing with Spiral Symplectic
Contact us
Open access team Report an issue
Other Services
Scholarly Communications Library Services
logo

Imperial College London

South Kensington Campus

London SW7 2AZ, UK

tel: +44 (0)20 7589 5111

Accessibility Modern slavery statement Cookie Policy

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback